Business Wire

Neat Launches Subscription Service for Zoom Customers Outside the US and Announces Additional Investment from Zoom

22.7.2020 16:00:00 EEST | Business Wire | Press release

Share

Neat, a Norwegian company whose pioneering team have been at the cutting edge of video communications for decades, today announced its Neat as a Service (NaaS) subscription offering. NaaS makes it quick and easy for Zoom customers outside the US to deploy Neat hardware devices in their meeting spaces. Neat and Zoom have also disclosed that Zoom Video Communications, Inc. (NASDAQ: ZM) has made an additional financial investment in Neat.

"Zoom and Neat together are making it easy for customers to expand their video conferencing capabilities. Our additional investment in Neat reflects our conviction that Neat's devices are an outstanding complement to Zoom's communications platform," said Eric S. Yuan, Zoom CEO. "We believe Neat offers innovative technology that ensures Zoom customers enjoy an incredible meeting room experience."

Aligned with Zoom's recently introduced Hardware as a Service (HaaS), NaaS is provided directly by Neat and expands the reach of Zoom HaaS beyond the US, enabling Zoom customers globally to consume Neat devices. Among other things, it's an ideal solution for customers with offices and teams scattered throughout different countries, as they can ensure a consistent global experience for all users.

As the new normal forces people around the world to adapt their ways of working, both in offices and remotely, video conferencing is proving to be a key tool in supporting continued productivity and driving stronger collaboration. NaaS makes it seamless for customers with a Zoom Rooms license to equip their meeting spaces with any of Neat's world-class devices: Neat Bar and Neat Pad, and Neat Board when it begins shipping at the end of October. With easy ordering and set up, customers can quickly enjoy all the benefits of deploying Zoom Rooms the Neat way, including receiving all the latest software releases and support from Zoom.

"Zoom customers globally are transitioning back to a mix of office and remote work, and need a scalable, cost-effective way to quickly expand their Zoom deployments in their meeting spaces," said Jeff Smith, Head of Zoom Rooms, Zoom. "Neat's innovative devices deliver a great user experience and are easy to install and manage. NaaS builds on that by giving customers the purchasing flexibility and choice they need."

"Subscription models such as Neat as a Service are the future of video conferencing since they eliminate expensive up-front costs and the complexity of deployment and ongoing support," said Roopam Jain, Industry Director, Unified Communications and Collaboration at Frost and Sullivan. "Video meetings are a better way to connect and collaborate. Particularly today, users need video that just works, whether they are in their home offices or meeting rooms."

Customers currently pay for their Zoom Rooms licenses through a subscription service from Zoom. With NaaS, they can use a subscription model for Neat devices as well, making the budgeting and managing of their Zoom Rooms even simpler.

NaaS is available now at neat.no and offers a 24-month plan with flexible payment options so customers can select the plan that best suits their requirements and budget. Neat Bar subscriptions start from as low as US$ 100/mo with an annual billing option. After the initial 24-month term, customers can then choose to upgrade their Neat system for the latest model with the newest hardware technology. Customers can also easily add further Neat devices to their existing plan to keep everything on a single contract.

"Neat was designed for Zoom, with the sole purpose of delivering a delightful meeting room experience to Zoom customers. We have achieved that by providing Zoom customers around the globe with our beautifully designed, simple to set up, feature-rich devices," said Simen Teigre, Neat CEO. "NaaS is the next step in our mission, offering a flexible subscription service that allows businesses to expand their Zoom solution with Zoom Rooms in a hassle-free way."

About Neat

Neat designs simple and elegant video meeting devices that just work. The company was founded in Oslo, Norway, by a team that for decades have shaped game-changing innovations for some of the most recognized brands in video communications. All Neat products are available to buy directly online from neat.no and ship globally. Offering unique features, they are easy to set up and use, making Zoom Rooms the smoothest and best it's ever been. For more information on Zoom Rooms the Neat way, visit neat.no or @neat_no.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amy Martin
Media Relations
amy.martin@neat.no
+1 408 391 5194

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye